louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05520333: Brief Intervention to Prevent Alcohol Socialization (BIPAS Alcohol)
Official title: Brief Intervention to Prevent Alcohol Socialization / Better Informed Parents Keeping Adolescents Safe From Alcohol (BIPAS Alcohol)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alcohol Drinking, Adolescent
Drinking Behavior
Drinking, Alcohol
Adolescent Behavior
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
Collaborators: name: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First posted: 2022-08-29
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Early alcohol socialization occurs within the family. This multi-level, high-reach, low-intensity intervention to prevent early alcohol use capitalizes on the influence of providers, immunization timing, and pediatric guidelines that advise healthcare providers to give anticipatory guidance about early alcohol use. In conjunction, the intervention capitalizes on the power of technology to reinforce and expand upon pediatrician messages.

The study seeks to understand the feasibility and effectiveness of a pilot intervention designed to prevent alcohol socialization through education of parents of rising 6th grade students.


Eligibility criteria: Inclusion Criteria:

* 18 years or older;
* Parent or guardian of an enrolled child at a study clinic;
* Cohabitate part time (2 days/week) or more with enrolled child;
* Be able to complete study activities in English;
* Be able to give informed consent;
* Own a phone with text message capabilities and access to internet.

Exclusion Criteria:

* Families in which the 10-to-12-year old child is actively receiving treatment for alcohol use disorder.

Primary outcomes:
measure: Change in Mean Value of Parental Pro-sipping Beliefs Score
timeFrame: Baseline, three months
Secondary outcomes:
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: University of North Carolina at Chapel Hill
state: North Carolina
Study officials:
affiliation: UNC Chapel Hill
name: Melissa Gilkey, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01342133: Sweat Duct Imaging in Mother/Newborn Dyads
Official title: Sweat Duct Imaging in Mother/Newborn Dyads
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: X-Linked Hypohidrotic Ectodermal Dysplasia
Lead sponsor: Edimer Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2011-04-27
Enrollment: 28
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study will enroll up to twenty healthy term newborns and their mothers in the Assessment Nursery at Barnes-Jewish Hospital.

Brief summary: The purpose of this study is to evaluate sweat duct number on the plantar surface of newborn infants using a non-invasive confocal microscopy device.

Detailed description: In this exploratory study, the investigators propose to evaluate sweat duct number on the plantar surface of newborn infants using a non-invasive confocal microscopy device (Lucid Vivascope®). This approach has the potential to be valuable in repeated sweat endpoint assessments, as the device was selected based on its ease of use, the low risk to patients of all ages, and its ability to generate quantitative data.

Eligibility criteria: Inclusion Criteria:

* Healthy term newborns (37-42 weeks gestation at delivery) in the Assessment Nursery at Barnes-Jewish Hospital, St. Louis, MO
* Mother of a healthy term newborn who is enrolled in this study

Exclusion Criteria:

* Congenital abnormalities affecting skin, nails, or hair in the newborn infant
* Family history of a sweating disorder

Primary outcomes:
measure: Demonstrate the use of a confocal microscope to quantify sweat ducts on the plantar surface of healthy, term newborns
timeFrame: Day 1
measure: To assess the sweat duct density (i.e. the number of sweat ducts) in a 6 x 6 mm area on the plantar surface of healthy, term newborns, males and females, and the palmar surface of their mothers
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Lisa Moscoso, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Washington University School of Medicine
name: Dorothy K Grange, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01544933: The Influence of the Ribs on the Gravity of Burst Thoracic Spine Fractures
Official title: The Influence of the Ribs on the Gravity of Burst Thoracic Spine Fractures
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Burst Thoracic Spine Fractures
Keywords: spinal fractures
Thoracic vertebrae
spinal canal
kyphosis
Lead sponsor: Universidade de Passo Fundo
Sponsor class: OTHER
First posted: 2012-03-06
Enrollment: 2
Sex: ALL
Minimum age (years): 17
Maximum age (years): 79
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with burst fractures of the thoracic spine treated by the Hospital Ortopedico de Passo Fundo

Brief summary: The purpose of this study is to analyse the anatomic influence of the ribs related to the incidence and severity of burst spine fractures.

Detailed description: To analyse the anatomic influence of the ribs related to the incidence and severity of burst spine fractures, with the measurements of kyphosis, vertebral collapse and vertebral canal narrowing

Eligibility criteria: Inclusion Criteria:

* burst fractures in thoracic spine

Exclusion Criteria:

* fractures that were not burst fractures in thoracic spine

Primary outcomes:
measure: residual kyphosis
timeFrame: 3 years
Secondary outcomes:
measure: vertebral canal narrowing
timeFrame: 3 years
Other outcomes:
Locations:
city: Passo Fundo
country: Brazil
facility: Rodrigo Tisot
state: RS
Study officials:
affiliation: Hospital Ortopedico de Passo Fundo
name: Rodrigo A Tisot, Dr
role: STUDY_DIRECTOR
References:
Clinical trial NCT02527733: Retinal Sensitivity in BRVO After Anti-VEGF Therapy
Official title: Retinal Sensitivity in Branch Retinal Vein Occlusion After Anti-VEGF Therapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Branch Retinal Vein Occlusion
Lead sponsor: Fukushima Medical University
Sponsor class: OTHER
First posted: 2015-08-19
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The efficacy of anti-vascular endothelial growth factor (VEGF) therapy for branch retinal vein occlusion (BRVO) is shown, but its effect on retinal sensitivity is not fully investigated. The purpose of this study is to compare the changes in retinal sensitivity after ranibizumab therapy or combination therapy of ranibizumab and laser photocoagulation in eyes with BRVO.


Eligibility criteria: Inclusion Criteria:

* Treatment naive patients of branch retinal vein occlusion with visual acuity of less than 1.0 and macular edema of more than 250 micrometers in foveal thickness.

Exclusion Criteria:

* Patients with history of treatment for branch retinal vein occlusion, possibility of pregnancy, allergy for ranibizumab, intraocular infection, or severe inflammation will be excluded.

Primary outcomes:
measure: Retinal sensitivity measured by microperimetry (MP-3, NIDEK, Japan)
timeFrame: At 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Fukushima
country: Japan
facility: Department of Ophthalmology, Fukushima Medical University
Study officials:
References:
Clinical trial NCT03501433: Effects of Nicotinamide Riboside on Metabolism and Vascular Function
Official title: Effects of Nicotinamide Riboside on Metabolism and Vascular Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aging
Lipemia
Keywords: postpandial
lipemia
microvascular
Lead sponsor: Iowa State University
Sponsor class: OTHER
First posted: 2018-04-18
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomized, cross-over
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.

Detailed description: The purpose of this study is to determine the effects of 7 days of Nicotinamide Riboside (NR) or placebo supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.

Eligibility criteria: Inclusion Criteria:

* Age 18 to 35 (young) and 60 to 75 (older)
* Normo- or pre-hypertensive (blood pressure \<140/90 mmHg)
* Non-smokers
* Able to give informed consent and participate in all laboratory visits

Exclusion Criteria:

* Currently taking any medications that could interfere with cardiovascular or metabolic outcomes will be excluded from the study (e.g., beta-blockers)
* Known metabolic (e.g. Type I or Type II diabetes, cardiovascular disease, etc.) or immunologic (e.g. HIV, cancer, autoimmune, etc.) diseases
* Food allergies to egg, milk, soy or wheat
* Women who are pregnant or planning to become pregnant during the course of the study,
* Pacemaker or other implanted device
* Unwilling to participate in the experimental protocol or blood draws will be excluded

Primary outcomes:
measure: NAD+
timeFrame: 7 days
Secondary outcomes:
measure: Vasodilatory responsiveness
timeFrame: 7 days
measure: Lipdemia
timeFrame: 7 days
measure: Oxidative stress and inflammation
timeFrame: 7 days
Other outcomes:
Locations:
city: Ames
country: United States
facility: Iowa State University
state: Iowa
Study officials:
affiliation: Iowa State University
name: Rudy Valentine, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00213733: Molecular Assessment of Lymph Nodes in Patients With Resected (Stage I to IIIA) Non-small Cell Lung Cancer
Official title: Research of Molecular Markers for Diagnosis and/or Prognosis in Lymph Node Metastasis of Resected Non-small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Keywords: Lung cancer patients
non-small cell lung cancer
molecular marker
lymph node completed resected
Lung cancer samples and paired lymph node resected
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2005-09-21
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with resectable non-small cell lung cancer (stage I to IIIA), with a complete resection of the tumor and paired lymph nodes

Brief summary: This is a prospective study of surgically resected samples and lymph nodes of lung cancer patients. For histopathologically positive lymph nodes from a complete resection, the investigators would like to analyse tumor tissue by allelotyping and comparing these results with those observed in the primary lung tumor to establish a cartography of molecular alteration in resected lung cancer. For non histopathologically positive lymph nodes, the investigators would like to research the presence (or not) of micrometastasis by allele-specific PCR (polymerase chain reaction).

Detailed description: Genetic: It is a prospective study during two years with three years for follow-up. No control group is recruited.

Eligibility criteria: Inclusion Criteria:

* Patients with resectable non-small cell lung cancer (stage I to IIIA), with a complete resection of the tumor and paired lymph nodes.
* Informed consent is required.

Exclusion Criteria:

* Another cancer
* Chemotherapy before surgical treatment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Chirurgie Thoracique, Hôpital Civil
city: Strasbourg
country: France
facility: Service de Pneumologie, Hôpital Lyautey
city: Strasbourg
country: France
facility: Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital de Hautepierre
city: Strasbourg
country: France
facility: Service d'Anatomie Pathologique, Hôpital de Hautepierre
city: Strasbourg
country: France
facility: Service de Pneumologie, Hôpital de Hautepierre
Study officials:
affiliation: Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital de Hautepierre
name: Michèle BEAU-FALLER, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05405933: Comparison of Propioceptive Neuromuscular Facilitation Vs Balance Exercise Along With Conventional Therapy for Balance and Gait in Chronic Parkinson's Patient
Official title: Comparison of Propioceptive Neuromuscular Facilitation Vs Balance Exercise Along With Conventional Therapy for Balance and Gait in Chronic Parkinson's Patient
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Parkinson
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2022-06-06
Enrollment: 60
Sex: ALL
Minimum age (years): 42
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: To determine the effect of Proprioceptive Neuromuscular Facilitation Vs Balance Exercise along with Conventional Therapy for balance and gait in Chronic Parkinson's patients.


Eligibility criteria: Inclusion Criteria:

* Chronic Parkinson's patients.(34)
* Patients from both gender around the age of 45-65.(35)
* Patient with a score of 42 above on the Berg Balance Scale.(29)
* Patient with good cognitive function minimum score of 20 or more on Mini-mental Status Examination Scale (MMSE).(36)

Exclusion Criteria:

* Patients with a history of recurrent stroke.(37)
* Patient with peripheral vascular disease.(38)
* Patient with fracture or dislocation of lower limb.(39)
* Patient with peripheral nerve injury.(40)
* Patient with skin discoloration, skin ulcers, and skin allergy.(41)

Primary outcomes:
measure: Balance Exercise Along With Conventional Therapy
timeFrame: 6 Months
measure: Propioceptive Neuromuscular Facilitation
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: General hospital Jinnah hospital Mayo hospital Chaudhry Muhammad Akram Teaching and research hospital Services hospital Lahore (SHL)
Study officials:
References:
Clinical trial NCT05894733: The Effects of Frequent Follow up on Compliance in Patients Receiving PAP Therapy Due to OSA (Pap: Positive Airway Pressure, OSA: Obstructive Sleep Apnea )
Official title: The Effects of Frequent Follow up on Compliance in Patients Receiving PAP Therapy Due to OSA
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patient Compliance
Sleep Disorder
Obstructive Sleep Apnea of Adult
Lead sponsor: Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital
Sponsor class: OTHER
First posted: 2023-06-08
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The investigators planned to investigate the effect of close monitoring on compliance and the factors affecting compliance among patients receiving PAP treatment due to OSA.This study was a single-center, prospective, randomized, controlled study approved by the hospital's ethics committee.One hundred twenty-eight patients were randomized as group one or two as group 1 is the study and group 2 is the control group. The first group was called by phone on the 15th day to ask if there were any complaints or problems with the device. Sequentially, they were called for controls at the end of the first, third, and sixth months.

The second group was accepted as the control group, following our clinic's standard procedure in the first and sixth months. The patients who came to the control were asked if there were any problems with the device and any difficulties in use, and they were again informed about the devices and masks.


Eligibility criteria: Inclusion Criteria:, .newly diagnosed OSA with PSG , and underwent PAP titration

Exclusion Criteria:

. unfollowed patients

Primary outcomes:
measure: follow-up
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Maltepe
country: Turkey
facility: Makbule Özlem
state: İstanbul
Study officials:
affiliation: sureyyapasa chest diseases center
name: makbule özlem akbay, md
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03925233: Breast Cancer Treatment Based on Organ-like Culture
Official title: Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Breast Cancer Organoids
Keywords: Drug sensitivity experiment
Resistance mechanism research
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2019-04-24
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: With the prolongation of human life and lifestyle changes, the incidence and mortality of cancer has increased year by year. Since 2010, cancer has become the leading cause of death. Among women, the incidence of breast cancer is the highest, and it shows a growing trend, which seriously threatens women's health. Breast cancer has a high degree of tumor heterogeneity, which leads to a great difference in sensitivity to chemotherapy among affected individuals. The drug resistance after chemotherapy leads to poor prognosis. Therefore, screening for breast cancer tumor cells is sensitive to chemotherapy. Molecular level studies of drug resistance are necessary.

Brief summary: Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.


Eligibility criteria: Inclusion Criteria:

Patients with breast cancer and the largest tumor diameter ≥ 3cm No previous chemotherapy regimen age 18-65 years old Can obtain the tumor tissue specimens required for culture Heart, liver, kidney and bone marrow hematopoietic function is good Know and sign the informed consent form

Exclusion Criteria:

Pregnant or lactating women Also suffering from other cancer patients There are serious uncontrolled medical diseases or acute infections Those who are known to be allergic to this study drug or a variety of previous drugs The patient cannot understand the purpose of the study or disagree with the requirements of the study.

Other investigators believe that patients who are not suitable for this study group

Primary outcomes:
measure: Detection of cell viability
timeFrame: 8 weeks before neoadjuvant chemotherapy
Secondary outcomes:
measure: Detection of in vitro model drug sensitivity
timeFrame: 8 weeks before neoadjuvant chemotherapy
measure: Clinical efficacy assessment according to RECIST criteria
timeFrame: 8 weeks before neoadjuvant chemotherapy
Other outcomes:
Locations:
city: Xi'an
country: China
facility: JingSu
state: Shaanxi
Study officials:
References:
Clinical trial NCT02538133: Study Assessing Hybrid SPECT-CT With Labeled Leukocytes for Diagnosis of Vascular Prosthesis Infections
Official title: Tomoscintigraphie Hybride Aux Leucocytes Marqués Dans le Diagnostic Des Infections de Prothèses Vasculaires.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Vascular Prosthesis Infection
Keywords: 99mTc-Exametazime (HMPAO)-Labeled Leukocytes
suspected subdiaphragmatic vascular prosthesis infection
diagnosis
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2015-09-02
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Vascular Prothesis Infection is a rare but an extremely serious complication. Diagnosis is often difficult (germs are found only in 50% of cases). Conventional imagery is often non-specific and difficult to interpret especially in early postoperative phase. Leukocytes isolated from the patient's blood are labeled with a radiopharmaceutical technetium 99mTc-HMPAO.

The aim of this study is to assess the overall diagnostic performance of scintigraphy (hybrid SPEC-CT) with labeled leucocytes in diagnosis of subdiaphragmatic vascular prothesis infection.


Eligibility criteria: Inclusion Criteria:

* patient of more than 18 years old
* Patient with a subdiaphragmatic vascular prosthesis
* Vascular prosthesis infection suspected with clinical (flow from the scare and/or local pain and/or erythema and/or persistent fever and/or bacteraemia) and/or biological (inflammatory syndrome : elevated C-reactive protein and/or erythrocyte sedimentation rate (ESR) and/or white blood cells increased) infection signs
* Patient willing to participate with a signed informed consent
* Patient covered by a healthcare insurance

Exclusion Criteria:

* Pregnant women or of childbearing age without effective contraception
* Prosthesis limited to a bare stent.
* Patient who has been committed to an institution by legal or regulatory order
* Contraindications for labeled leukocytes scintigraphy realization :
* Restlessness, inability to keep still lie at least 1 hour
* Claustrophobia
* Poor compliance predictable or impaired general condition making it impossible to carry out the examination
* Refusal to participate in the study

Primary outcomes:
measure: Percentage of patients correctly classified by interpreting scintigraphy for the diagnosis of vascular prosthesis infection. The percentage of patients correctly classified is assessed comparing with the diagnostic established by the expert committee.
timeFrame: One year after inclusion when vascular prosthesis infection is suspected and hybrid SPEC-CT with labeled leukocytes has been performed.
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: CHU
city: Le Mans
country: France
facility: CH
city: Strasbourg
country: France
facility: CHRU
Study officials:
affiliation: University hospital, Angers, FRANCE
name: HERVE RAKOTONIRINA, Dr
role: PRINCIPAL_INVESTIGATOR
References: